Wuhan Hvsen Biotechnology Co Ltd
Wuhan Hvsen Biotechnology Co.,Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company offers tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. It produces various vet… Read more
Wuhan Hvsen Biotechnology Co Ltd (300871) - Total Assets
Latest total assets as of September 2025: CN¥2.96 Billion CNY
Based on the latest financial reports, Wuhan Hvsen Biotechnology Co Ltd (300871) holds total assets worth CN¥2.96 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Wuhan Hvsen Biotechnology Co Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Wuhan Hvsen Biotechnology Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Wuhan Hvsen Biotechnology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Wuhan Hvsen Biotechnology Co Ltd's total assets of CN¥2.96 Billion consist of 43.5% current assets and 56.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.8% |
| Accounts Receivable | CN¥454.36 Million | 15.1% |
| Inventory | CN¥248.16 Million | 8.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥114.44 Million | 3.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Wuhan Hvsen Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wuhan Hvsen Biotechnology Co Ltd's current assets represent 43.5% of total assets in 2024, a decrease from 53.4% in 2016.
- Cash Position: Cash and equivalents constituted 10.8% of total assets in 2024, down from 20.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 11.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 15.1% of total assets.
Wuhan Hvsen Biotechnology Co Ltd Competitors by Total Assets
Key competitors of Wuhan Hvsen Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Wuhan Hvsen Biotechnology Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Wuhan Hvsen Biotechnology Co Ltd generates 0.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Wuhan Hvsen Biotechnology Co Ltd is currently not profitable relative to its asset base.
Wuhan Hvsen Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.70 | 1.35 | 3.48 |
| Quick Ratio | 1.36 | 1.07 | 3.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥525.17 Million | CN¥ 316.18 Million | CN¥ 838.48 Million |
Wuhan Hvsen Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Wuhan Hvsen Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.57 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | 1.3% |
| Total Assets | CN¥3.01 Billion |
| Market Capitalization | $392.81 Million USD |
Valuation Analysis
Below Book Valuation: The market values Wuhan Hvsen Biotechnology Co Ltd's assets below their book value (0.13 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Wuhan Hvsen Biotechnology Co Ltd's assets grew by 1.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Wuhan Hvsen Biotechnology Co Ltd (2016–2024)
The table below shows the annual total assets of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.01 Billion | +1.32% |
| 2023-12-31 | CN¥2.98 Billion | -0.46% |
| 2022-12-31 | CN¥2.99 Billion | +9.03% |
| 2021-12-31 | CN¥2.74 Billion | +56.47% |
| 2020-12-31 | CN¥1.75 Billion | +169.54% |
| 2019-12-31 | CN¥650.08 Million | +39.32% |
| 2018-12-31 | CN¥466.60 Million | +35.57% |
| 2017-12-31 | CN¥344.18 Million | +34.52% |
| 2016-12-31 | CN¥255.86 Million | -- |